Table 6.

Overview of malignancies in the short-term and cumulative analyses from the 8 integrated trials. Data show incidence rates (IR) per 100 patient-years (95% Poisson CI).

Short-term PeriodCumulative Period, n = 4149
Placebo + Background Therapy, n = 1099IV Abatacept + Background Therapy, n = 3173
Total malignancies (excluding nonmelanoma skin cancer)Patients with event, n51788
IR (95% CI)0.59 (0.19, 1.37)0.73 (0.42, 1.17)0.73 (0.58, 0.89)
Lymphoma*Patients with event, n019
IR (95% CI)00.04 (0.00, 0.24)0.07 (0.03, 0.14)
Solid organ cancers (combined)Patients with event, n51572
IR (95% CI)0.59 (0.19, 1.37)0.64 (0.36, 1.06)0.59 (0.46, 0.75)
Lung cancerPatients with event, n0518
IR (95% CI)00.21 (0.07, 0.50)0.15 (0.09, 0.23)
Breast cancerPatients with event, n2314
IR (95% CI)0.23 (0.03, 0.85)0.13 (0.03, 0.38)0.12 (0.06, 0.19)
Nonmelanoma skin cancerPatients with event, n71987
IR (95% CI)0.82 (0.33, 1.70)0.82 (0.49, 1.28)0.73 (0.58, 0.90)
  • * Lymphoma refers to combined incidences of lymphoma, including extranodal marginal zone B cell lymphoma (MALT type), diffuse large B cell lymphoma, T cell lymphoma, and non-Hodgkin’s lymphoma. IV: intravenous.